Monitor the VOCERYQ commercial launch trajectory and cash burn rate. The $80.5M raise extends runway only into late Q4 2027, implying another capital event may be needed within 12 months if revenue ramp is slow. Watch for early prescription data and reimbursement updates.
Drug in focus
INO drug pipeline →VOCERYQ
● Neutral Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
- Next catalyst
- None dated
What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.51entry
- T+1 · 7d ago −3.97%α −3.61% · $1.45
- T+5 · 20h ago −7.28%α −5.59% · $1.40
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inovio Pharmaceuticals filed an 8-K reporting the entry into an underwriting agreement for a $75M public offering of 58.7M common shares and pre-funded warrants for 12.7M shares, with the underwriters exercising their option to purchase an additional 10.7M shares in full. Net proceeds are expected to be approximately $80.5M, which management believes will fund operations into late Q4 2027. The offering follows the recent FDA accelerated approval of VOCERYQ and comes just days after a prior 424B5 filing for the same $75M raise, confirming acute capital needs at a $150M market cap with massive dilution.
Key Facts
- Priced 58,747,235 common shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049/warrant
- Underwriters exercised in full the 30-day option for 10,714,285 additional shares
- Net proceeds expected to be approximately $80.5 million
- Pre-funded warrants have an exercise price of $0.001 per share
- Offering closed on November 9, 2026
- Proceeds will fund operations into late Q4 2027 per management guidance
- Offering follows October 30 FDA accelerated approval of VOCERYQ (INO-3107) for RRP
- Prior 424B5 filing on November 6 disclosed $75M offering at a 27.6% discount to last sale price
- Company had only $48.4M cash as of September 30, 2026 with a going concern warning
- Total dilution: 69.5M shares (58.7M + 10.7M option) plus 12.7M warrant shares = 82.2M new shares, approximately 53% of pre-offering shares outstanding
Financial Impact
Approximately $80.5 million net proceeds from a $75M gross offering plus full exercise of the greenshoe, representing massive dilution of roughly 53% of pre-offering shares outstanding at a $150M market cap.
Risk Factors
- Massive dilution of approximately 53% of pre-offering shares outstanding
- Going concern warning prior to this raise signals ongoing capital insufficiency
- Proceeds only extend runway into late Q4 2027, requiring additional financing
- VOCERYQ commercial launch is unproven; revenue may not materialize as expected
- Stock price may face continued pressure from the 27.6% discount pricing and overhang from warrant exercise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452658 |
| Document: d192373dex41.htm | 0001193125-26-452658 |
| Document: d192373d8k.htm | 0001193125-26-452658 |
| Document: d192373dex51.htm | 0001193125-26-452658 |
| Document: d192373dex992.htm | 0001193125-26-452658 |
| Document: d192373dex991.htm | 0001193125-26-452658 |
| Document: 0001193125-26-452658-index-headers.html | 0001193125-26-452658 |
| Document: 0001193125-26-452658-index.html | 0001193125-26-452658 |
| Document: 0001193125-26-452658.txt | 0001193125-26-452658 |
Track record
20 reports on INO
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Viewing Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers